Original articles

Sletten ET, Arnes M, Vereide AB, Ørbo A (2019)
Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study
Anticancer Res, 39 (9), 4897-4903
DOI 10.21873/anticanres.13676, PubMed 31519593

Sletten ET, Arnes M, Vereide AB, Ørbo A (2018)
Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study
Anticancer Res, 38 (5), 2883-2889
DOI 10.21873/anticanres.12534, PubMed 29715112

Sletten ET, Arnes M, Lysa LM, Moe BT, Straume B, Orbo A (2017)
Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study
Anticancer Res, 37 (5), 2529-2536
DOI 10.21873/anticanres.11595, PubMed 28476823

Ørbo A, Arnes M, Lyså LM, Borgfeldt C, Straume B (2016)
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
Br J Cancer, 115 (9), e15
DOI 10.1038/bjc.2016.330, PubMed 27711084

Ørbo A, Arnes M, Lyså LM, Borgfeldt C, Straume B (2016)
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
Br J Cancer, 115 (6), 725-30
DOI 10.1038/bjc.2016.247, PubMed 27537387

Ørbo A, Arnes M, Lyså LM, Straume B (2015)
Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia
Anticancer Res, 35 (12), 6401-9
PubMed 26637849

Arnes M, Hvingel B, Orbo A (2014)
Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study
Anticancer Res, 34 (5), 2319-24
PubMed 24778038

Eggen T, Sager G, Arnes M, Pettersen I, Ørbo A (2011)
Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix
Anticancer Res, 31 (6), 2319-25
PubMed 21737658

Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B (2010)
Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system
Acta Obstet Gynecol Scand, 89 (11), 1438-46
DOI 10.3109/00016349.2010.512068, PubMed 20955098

Ørbo A, Kaino T, Arnes M, Larsen K, Pettersen I, Moe B (2009)
Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction
Acta Obstet Gynecol Scand, 88 (11), 1234-42
DOI 10.3109/00016340903281014, PubMed 19900140

Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K (2008)
Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only
Gynecol Oncol, 111 (1), 68-73
DOI 10.1016/j.ygyno.2008.06.014, PubMed 18684496

Eggen T, Arnes M, Moe B, Straume B, Orbo A (2007)
Prognosis of early cervical cancer (FIGO Stages IA2, IB, and IIA) in northern Norway predicted by malignancy grading score and objective morphometric image analysis
Int J Gynecol Pathol, 26 (4), 447-56
DOI 10.1097/pgp.0b013e3180341111, PubMed 17885497

Vereide AB, Kaino T, Sager G, Arnes M, Ørbo A (2005)
Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia
Gynecol Oncol, 101 (2), 214-23
DOI 10.1016/j.ygyno.2005.10.030, PubMed 16325240